Myfenax (Mycophenolate Mofetil)

• Myfenax (mycophenolate mofetil) is used in immune‑mediated conditions where suppression of lymphocyte activity is required.
• Organ transplant rejection: helps prevent rejection of kidney, heart and liver transplants.
• Lupus nephritis: reduces kidney inflammation in systemic lupus erythematosus.
• Dermatomyositis: used as part of combination therapy to control disease activity.
• Vasculitis: employed in refractory cases to suppress immune response.
• Other autoimmune diseases: may be added to regimens for severe autoimmune disorders.

• Mycophenolate mofetil is converted intracellularly to mycophenolic acid, which selectively inhibits inosine monophosphate dehydrogenase (IMPDH). This blockade reduces guanine nucleotide synthesis, a critical step for DNA replication in activated T‑ and B‑lymphocytes, thereby suppressing their proliferation and dampening the immune response.

Myfenax may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Diarrhea: loose stools, sometimes watery.
• Headache: intermittent tension‑type pain.
• Tremor: fine shaking of hands.
• Abdominal pain: cramping or discomfort.
• Fatigue: general tiredness.

Serious or Rare Side Effects

• Severe infections: opportunistic bacterial, viral or fungal infections.
• Bone marrow suppression: leukopenia, anemia or thrombocytopenia.
• Hepatic toxicity: elevated liver enzymes or hepatitis.
• Malignancy risk: increased incidence of certain cancers.
• Progressive multifocal leukoencephalopathy (PML): rare but life‑threatening brain infection.
• Teratogenicity: birth defects when exposure occurs in pregnancy.

• Before initiating Myfenax, several safety considerations should be reviewed.
• Pregnancy: contraindicated (Category X) due to high teratogenic risk.
• Infection risk: monitor for signs of opportunistic infections.
• Hematologic monitoring: perform regular CBC to detect leukopenia or anemia.
• Renal function: adjust dosing in severe renal impairment.
• Drug interactions: review concomitant medicines for potential CYP or absorption interactions.
• Store at room temperature: keep in the original container, protect from moisture and light.

Myfenax interacts with several drugs; some require avoidance while others need close monitoring.

Major Interactions (Avoid)

• Cyclosporine: increased mycophenolate exposure, raising toxicity risk.
• Tacrolimus: similar interaction leading to higher drug levels.
• Live vaccines: risk of severe infection due to immunosuppression.
• Antacids containing aluminum or magnesium: reduce mycophenolate absorption.

Moderate Interactions (Monitor Closely)

• Azathioprine: additive bone‑marrow suppression.
• Rifampin: may lower mycophenolate concentrations.
• Warfarin: potential increase in INR, requiring INR monitoring.